•
Mar 31, 2022

Glaukos Q1 2022 Earnings Report

Announced financial results for the first quarter of 2022.

Key Takeaways

Glaukos Corporation announced financial results for the first quarter ended March 31, 2022, with net sales of $67.7 million. The company updated its 2022 net sales guidance to $270 million to $275 million.

Net sales of $67.7 million in Q1 2022.

Glaucoma net sales of $51.5 million and Corneal Health net sales of $16.1 million in Q1 2022.

Gross margin of approximately 75% and non-GAAP gross margin of approximately 83% in Q1 2022.

Operating expenses of $40.8 million and non-GAAP operating expenses of $69.8 million in Q1 2022.

Total Revenue
$67.7M
Previous year: $68M
-0.4%
EPS
-$0.38
Previous year: -$0.21
+81.0%
Gross margin
75%
Previous year: 76%
-1.3%
Non-GAAP gross margin
83%
Previous year: 84%
-1.2%
SG&A expenses
$43.9M
Previous year: $41.9M
+4.9%
Gross Profit
$50.6M
Previous year: $51.7M
-2.1%
Cash and Equivalents
$106M
Previous year: $417M
-74.5%
Free Cash Flow
$3.17M
Previous year: -$13M
-124.4%
Total Assets
$1.05B
Previous year: $1.02B
+2.9%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2022 net sales to be in the range of $270 million to $275 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income